Abstract
While new anticancer angiogenesis inhibitors present a well-tolerated safety profile, they are not without adverse events. The signaling pathways and/or receptors inhibited by these new drugs are often physiologically expressed in the skin and/or hair follicle and cutaneous toxicity is on the forefront. This article reviews the main dermatologic adverse events induced by these targeted anticancer therapies with a partial or exclusive antiangiogenic activity: sorafenib, sunitinib, pazopanib, vandetanib, everolimus, temsirolimus or bevacizumab.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / adverse effects*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Benzenesulfonates / adverse effects
-
Bevacizumab
-
Drug Eruptions / etiology*
-
Humans
-
Indazoles
-
Indoles / adverse effects
-
Molecular Targeted Therapy / adverse effects
-
Molecular Targeted Therapy / methods
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Piperidines / adverse effects
-
Pyridines / adverse effects
-
Pyrimidines / adverse effects
-
Pyrroles / adverse effects
-
Quinazolines / adverse effects
-
Skin / drug effects*
-
Sorafenib
-
Sulfonamides / adverse effects
-
Sunitinib
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Benzenesulfonates
-
Indazoles
-
Indoles
-
Phenylurea Compounds
-
Piperidines
-
Pyridines
-
Pyrimidines
-
Pyrroles
-
Quinazolines
-
Sulfonamides
-
Niacinamide
-
Bevacizumab
-
pazopanib
-
Sorafenib
-
Sunitinib
-
vandetanib